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Abstract Previously published data have shown an allele-
specific variation in the in vitro binding of apolipoprotein E
(apoE) to tau, which prompted the hypothesis that apoE binding
may protect tau from phosphorylation, apoE3 being more
efficient than apoE4. We have, therefore, investigated the effects
of apoE on tau phosphorylation in vitro by the proline-directed
kinase, glycogen synthase kinase (GSK)-3L. The phosphopeptide
maps of tau alone, of tau with apoE3 and of tau with apoE4 were
very similar. When apoE2 was present a further four spots were
evident. Additionally, of the 15 peptides phosphorylated in the
presence or absence of apoE, subtle differences, some isoform-
specific, in the relative amounts of phosphorylation were
observed. ß 2000 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The microtubule-associated protein tau is a phosphoprotein
predominantly expressed by neurones and contributes to the
stability and integrity of neuronal microtubules [1,2]. Regula-
tion of the role of tau in maintaining microtubule stability
appears to be largely through phosphorylation [3]. Increased
phosphorylation of tau results in a reduction in microtubule
binding and assembly competence [4^8] and it is noteworthy
that in tangle-bearing neurones in which hyperphosphorylated
tau comprises paired helical ¢laments (PHFs), microtubules
are absent [9,10]. To date, 25 phosphorylation sites have
been identi¢ed by sequence analysis in PHF-tau [11,12] and
many of these sites are serine or threonine residues followed in
sequence by proline. In vitro studies have shown that several
kinases can phosphorylate sites found in PHF-tau (reviewed
in [13]) but that in transfected cells overexpressing these ki-
nases it is only glycogen synthase kinase (GSK)-3L and GSK-
3K that phosphorylate tau to a comparable extent to that
found in vitro [14].
The only genetic variation unequivocally associated with
late-onset Alzheimer’s disease (AD) is allelic variability at
the apolipoprotein E (apoE) locus. Three common polymor-
phisms of the single apoE gene, alleles O2, O3 and O4, encode
isoforms di¡ering at two sites. Gene dosage of apoE O4 has
been shown to be a risk factor for late-onset familial and
sporadic forms of AD [15^19]. In vitro binding studies have
shown allele-speci¢c variation of interaction between tau and
apoE [20]. Whilst both apoE3 and apoE4 are able to bind tau
to some degree, apoE3 but not apoE4 is capable of resilient
association over a wide range of concentrations [21]. It has
been hypothesised, therefore, that apoE may play a protective
role, with apoE3 (and apoE2) binding to tau, interfering with
its hyperphosphorylation and so preventing or reducing mi-
crotubule instability and the formation of PHFs [22]. In this
study we have examined the e¡ect of the three common hu-
man apoE isoforms on the phosphorylation of tau by GSK-3L
by two-dimensional (2-D) phosphopeptide mapping and iden-
ti¢ed the sites of phosphorylation directly from the 2-D maps
using nano-electrospray (nano-ES) mass spectrometry (MS).
2. Materials and methods
2.1. Cloning and expression of human apoE2, E3 and E4 in baculovirus
pAc-E3 (kindly provided by Dr Alan D. Attie, Department of Bio-
chemistry, University of Madison), which is a derivative of pAcYM1
[23], was digested with BamHI to isolate the apoE3 cDNA. This frag-
ment was cloned into the vector pALTER1 (Promega, Madison, WI,
USA). Mutagenesis was done according to the manufacturer’s instruc-
tions. After mutagenesis, the apoE2 and apoE4 cDNA was cloned
into the BamHI restriction site of the baculovirus transfer vector
pAcYM1. The sequence of the apoE2 and apoE4 cDNA constructs
was veri¢ed by DNA sequencing prior to cotransfection.
Cotransfection of BaculoGoldTM baculovirus DNA (PharMingen,
San Diego, CA, USA) and the transfer vectors for apoE2, apoE3 and
apoE4 was performed using N-[1-(2,3-dioleoyloxypropyl)]-N,N,N-tri-
methylammonium propane (Boehringer Mannheim, Mannheim, Ger-
many) as transfection reagent. At day 4 after transfection, the super-
natant was collected and single virus clones were isolated as described
[23]. To produce recombinant apoE on a large scale, 2U106 Sf21 cells
per ml were seeded in a spinner £ask. The cells were infected with a
high-titre stock solution of recombinant baculovirus. After incubation
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at 27‡C for 72^96 h, the apoE-containing supernatant was collected
by centrifugation. Recombinant apoE was puri¢ed by a⁄nity chro-
matography on heparin-Sepharose 4B as previously described [24].
2.2. Expression of human apoE in cultured cells
Human apoE3 or apoE4 were expressed in HEK-293 cells stably
transfected with either human apoE3 or apoE4 cDNA and kindly
supplied by Dr Mary Jo LaDu, University of Chicago [25]. Condi-
tioned medium containing apoE was concentrated approximately 50-
fold using Amicon stirred ultra¢ltration cells (10 kDa membrane cut-
o¡). The concentrated medium was dialysed overnight at 4‡C against
phosphate-bu¡ered saline and ¢lter-sterilised before being quanti¢ed
by sodium dodecyl sulfate^polyacrylamide gel electrophoresis (SDS^
PAGE) and Coomassie brilliant blue staining against a recombinant
apoE standard of known concentration.
2.3. In vitro incubation of tau with apoE and phosphorylation with
GSK-3L
Recombinant human tau with one N-terminal insert and four re-
peat domains (1N4R) was produced in Escherichia coli as previously
described [26]. Rat GSK-3L was expressed in insect cells using a re-
combinant baculovirus supplied by J.R. Woodgett (Ontario Cancer
Institute, Toronto, Ont., Canada) and puri¢ed essentially by the
method of Hughes et al. [27], incorporating the modi¢cations of
Utton et al. [8]. The reaction conditions described below were used
when sites of phosphorylation on tau were to be determined by mass
spectrometric sequence analysis from the resulting 2-D phosphopep-
tide maps. For binding reactions, apoE (20 Wg) was incubated with
human tau (20 Wg) for 1 h at 37‡C in 200 Wl of 20 mM HEPES
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) bu¡er pH 7.4
(apoE:tau molar ratio of 2:1). Phosphorylation of human tau by
GSK-3L was carried out as described [28]. The reaction was termi-
nated by the addition of 0.1 ml of 100% (w/v) trichloroacetic acid and
left on ice for 5 min. Precipitated protein was collected by centrifu-
gation at 14 000Ugav for 5 min and the pellet washed twice with ice-
cold 20% (w/v) trichloroacetic acid then twice with ice-cold acetone.
Final washed material was resuspended in electrophoresis sample
bu¡er for analysis by SDS^PAGE. In a control set of experiments,
tau (2 g) was incubated with bovine serum albumin (BSA) (2, 4 and
10 Wg) for 1 h at 37‡C in the above bu¡er prior to phosphorylation.
2.4. Phosphopeptide mapping of tau
Radiolabelled human tau (20 Wg) in electrophoresis sample bu¡er
was resolved by 10% (w/v) acrylamide SDS^PAGE, then transferred
onto Immobilon P membrane (Millipore) at 15 V for 45 min. Protein
was visualised initially by staining the Immobilon P membrane with
0.1% (w/v) amido black solution [29] and radiolabelled protein iden-
ti¢ed by phosphorimage analysis on a Fujix Bas 1000 imager. The
phosphorylated tau bands were excised, counted by Cerenkov radia-
tion and then analysed by 2-D phosphopeptide mapping [28]. Phos-
phopeptides were visualised by exposing the cellulose plates to phos-
phorimage analysis and autoradiography at 370‡C. Corresponding
phosphopeptides were scraped from the two plates, pooled and pep-
tides eluted in 20% (v/v) acetonitrile in water by the method of A¡olt-
er et al. [30] for analysis by MS.
2.5. Nano-ES MS
Dried peptides eluted from the cellulose plates were dissolved in
0.5% (v/v) formic acid and desalted using a pulled glass capillary
self-packed with V5 Wl of POROS R3 sorbent (PerSeptive Biosys-
tems, Cambridge, MA, USA), as described by Wilm et al. [31]. The
desalted sample was eluted with 5 Wl of 50% (v/v) MeOH, 5% (v/v)
formic acid into a 500 Wl Eppendorf tube, centrifuged (14 000Ugav for
1 min) and 1 Wl inserted into the spraying needle. Electrospray mass
spectra were acquired on an API III triple quadrupole machine (PE-
Sciex, Ont., Canada) equipped with a nano-ES ion source developed
by Wilm and Mann [32,33] as described previously [12,34].
2.6. Statistical analysis
For quantitative studies, densitometric analysis of peptide spots
resolved by 2-D electrophoresis was performed. Single spots on
scanned autoradiographs or phosphorimages of the 2-D maps were
identi¢ed and, using MetaMorph image analysis software, optical
density of each spot determined by thresholding using the same cri-
teria in each case. Five samples from separate experiments for tau
phosphorylated by GSK-3L alone and tau phosphorylated in the pres-
ence of apoE2, apoE3 or apoE4 and two from tau phosphorylated in
the presence of BSA were measured. The total density for each spot
was calculated as a percentage of the sum of the density of all mea-
sured spots in each chromatogram (the unresolved mass of aggregated
spots close to the origin was not analysed). The resulting mean rela-
tive values for each spot for the ¢ve separate samples for each experi-
ment were compared using ANOVA with Bonferroni correction for
multiple testing using the SPSS statistical package.
3. Results
3.1. Phosphopeptide mapping analysis of recombinant
human tau
Recombinant human tau of the isoform containing one
amino-terminal region and four microtubule binding domains
(1N4R) phosphorylated with GSK-3L in the presence of
[Q-32P]ATP was digested with trypsin and the radiolabelled
phosphopeptides separated by 2-D electrophoresis and thin
layer chromatography. Autoradiographic analysis of the re-
sulting peptide map revealed 15 consistently well-resolved ra-
diolabelled phosphopeptide spots. A representative example
of the phosphopeptide maps is illustrated in Fig. 1. In most
experiments, some radiolabelled material, which may repre-
sent incompletely digested peptides, remained close to the ori-
gin. Resolved spots were individually scraped from two thin
layer cellulose plates, and then pooled for extraction of the
constituent peptide(s).
3.2. Identi¢cation of phosphopeptides and sites of
phosphorylation
Phosphopeptides which were extracted from the 2-D phos-
phopeptide maps of GSK-3L-phosphorylated human tau
(1N4R) (Fig. 1) were identi¢ed using nano-ES MS. Of the
15 spots, we were unable to identify four phosphopeptide
spots (spots 1, 7, 8, 13). Spots 3 and 12 each contained two
di¡erent phosphopeptides species, numbered 3a and 3b and
12a and 12b, respectively (Table 1).
A total of 12 sites phosphorylated by GSK-3L were identi-
¢ed (Table 1). The GSK-3L phosphorylation sites found in
human tau are located in two clusters on either side of the
microtubule binding domains, residues 181^235 and 396^404.
There is one exception to this; serine 262 which is located in
the ¢rst microtubule binding domain (Table 1). The GSK-3L-
Fig. 1. Phosphopeptide map analysis of tau phosphorylated by
GSK-3L. 20 Wg of recombinant human tau (1N4R) was incubated
with GSK-3L at 30‡C for V18 h in the presence of [Q-32P]ATP and
then analysed by SDS^PAGE and phosphopeptide mapping as de-
scribed in Section 2. The 15 numbered phosphopeptide spots which
were well-resolved were individually scraped from the plate, eluted
and analysed by MS.
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speci¢c inhibitor lithium markedly reduces phosphorylation at
all the above sites when included in the phosphorylation re-
action (data not shown).
3.3. The e¡ects of apoE on tau phosphorylation
Having established reproducible phosphopeptide maps of
GSK-3L-phosphorylated human tau isoform 1N4R and iden-
ti¢ed a majority of these sites, the e¡ects of apoE on tau
phosphorylation were investigated. Given previously reported
di¡erences in apoE binding apparently being dependent upon
the source of the protein [35], we have used two sources of
apoE in our studies ; ¢rstly, baculoviral expressed recombi-
nant apoE and, secondly, apoE from tissue culture medium
of cells stably expressing di¡erent human apoE isoforms. The
results did not di¡er with apoE source and for all quantitative
analysis baculoviral expressed recombinant apoE was used.
Prior to phosphorylation by GSK-3L, tau was incubated
with apoE2, E3, E4 or BSA as a control for 1 h at 37‡C.
Phosphopeptide maps of tau pre-incubated with recombi-
nant apoE2, apoE3 or apoE4 prior to phosphorylation by
GSK-3L were examined (Fig. 2). The autoradiographs shown
in Fig. 2 are representative of several experiments. The pattern
of phosphopeptide separation shown by the maps was broadly
similar to tau phosphorylated in the absence of apoE, with the
usual 15 resolved phosphopeptide spots. However, four addi-
tional spots were resolved on the maps when apoE2 was
Table 1
Phosphopeptides identi¢ed by nano-ES MS of peptides recovered from 2-D peptide maps of GSK-3L-phosphorylated recombinant human tau
(1N4R)
Spot Residues Sequence Average mass (Da) Site(s) identi¢ed
2 260^267 IGSpTENLK 940.9 262
3a 212^221 TpPSLPTPPTR 1146.2 212
3b 212^221 TPSLPTpPPTR 1146.2 217
4 210^221 SRTpPSLPTpPPTR 1469.4 212, 217
5 181^190 TpPPSSGEPPK 1076.1 181
6 231^240 TpPPKSpPSSAK 1159.1 231, 235
9 226^240 VAVVRTpPPKSPSSAK(+1P) 1683.8 231, (235, 237 or 238)
10 210^221 SRTpPSLPTPPTR 1389.5 212
11 231^240 TpPPKSPSSAK 1079.1 231
12a 386^406 TDHGAEIVYKSpPVVSpGDTSpPR 2455.3 396, 400, 404
12b 191^209 SGDRSpGYSSpPGSPGTPGSR 1968.8 195, 199
14 191^209 SGDRSpGYSSPGSPGTpPGSR 2048.8 195, 205 (198, 199 OR 202)
15 212^221 TpPSLPTpPPTR 1226.2 212, 217
Numbering according to the largest tau isoform. Sp and Tp represent phosphorylated serine or threonine residues. Spots 3 and 12 both con-
tained two distinct phosphopeptide species numbered 3a and 3b and 12a and 12b, respectively.
Fig. 2. Phosphopeptide map analysis of recombinant human tau 1N4R phosphorylated by GSK-3L in the absence of any apoE or in the pres-
ence of apoE2, apoE3 or apoE4. Tau was incubated in the absence or presence of apoE2, E3 or E4 for 1 h at 37‡C, prior to phosphorylation
by GSK-3L, SDS^PAGE and 2-D phosphopeptide mapping analysis were as described in the legend to Fig. 1. In the presence of apoE2 (B),
several new phosphopeptides (arrows) are found that are absent from the control (i.e. no apoE ^ A) and from phosphorylation in the presence
of apoE3 (C) or apoE4 (D).
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present (Fig. 2B) although, perhaps because of the small
amount of peptide in the spots, we have been unable to iden-
tify these phosphopeptides by mass spectrometric sequencing.
A quantitative analysis of the relative intensity of phos-
phorylation at the di¡erent sites as represented by spot inten-
sities (relative to the total) revealed di¡erences between the
absence and presence of apoE, and between apoE isoforms
(Fig. 3). The addition of apoE resulted in a decrease in rela-
tive phosphorylation of the peptide containing Thr231/Ser235
(spot 6) and an, as yet, unidenti¢ed phosphopeptide (spot 7)
and an increase in phosphorylation at Ser262 (spot 2) and a
peptide containing Thr212 (spot 10).
Of the isoform di¡erences, it was apparent that apoE4 re-
sulted in a signi¢cantly larger increase in phosphorylation at
the Thr212-containing peptide (spot 10) than the other two
apoE isoforms and a markedly reduced phosphorylation at a
Thr231-containing peptide (spot 11) when compared with
apoE2 or apoE3. Additionally, apoE4 did not reduce phos-
phorylation at the peptide containing both Thr231 and Ser235
(spot 6) to the same degree as either apoE2 or apoE3.
ApoE2 induced phosphorylation at four novel sites (Fig.
2B, arrows) when compared with tau alone or tau treated
with either apoE3 or apoE4. Relative to apoE3 or apoE4,
apoE2 signi¢cantly increased the intensity of the spot (spot
3) marking the presence of a mixture of small peptides con-
taining either phosphorylated Thr212 or Thr217. Interest-
ingly, this appears to be at the expense of the larger peptide
containing both sites (spot 4) which was reduced by apoE2
although the magnitude of the e¡ect just failed to reach sta-
tistical signi¢cance. The resolution of spots 13^15 from one
another was not reliable enough for the above analysis to be
carried out. In addition, spot 11 in the apoE4-treated sample
gave an average value close to zero.
In order to control for possible non-speci¢c e¡ects of the
presence of additional proteins on phosphorylation, phos-
phorylation was also conducted in the presence of BSA (molar
ratio tau:BSA of 1:1, 1:2 and 1:5). There was no signi¢cant
di¡erence between the maps produced by GSK-3L phosphor-
ylation of tau alone and tau with BSA, either in the pattern or
intensity of spots (data not shown).
4. Discussion
The hypothesis that apoE isoforms in£uence tau phosphor-
ylation derives from previous in vitro studies of isoform-spe-
ci¢c interactions of apoE with recombinant tau demonstrating
an avid binding with apoE3 but not apoE4, that did not
dissociate after electrophoresis on SDS gels run under non-
reducing conditions [20]. Here we demonstrate in the presence
of reducing agents an e¡ect of apoE isoforms on tau phos-
phorylation, as hypothesised [36], although the in£uence of
the di¡erent isoforms is complex. Firstly, some novel spots
were generated in the presence of apoE2 and secondly, a
change in the relative intensity in some spots was induced
by di¡erent apoE isoforms. The methods employed enabled
us to compare relative levels of phosphorylation at particular
sites with high sensitivity and accuracy.
In light of the recent discovery that recombinant GSK-3L
does not phosphorylate Ser262 [37], it is a surprise that our
baculovirus-derived GSK-3L kinase preparation does partially
phosphorylate this residue in vitro. However we found that
the GSK-3L-speci¢c inhibitor, lithium, markedly reduces
phosphorylation at this site. In fact Ser262 phosphorylation
was increased in the presence of all three isoforms of apoE,
possibly due to a conformational change resulting from the
association of apoE with tau. There were isoform-speci¢c var-
iations in phosphorylation at other sites. Notably, the Thr231/
Ser235 site was more protected by apoE2 than apoE4. Thr212
was signi¢cantly more phosphorylated when apoE4 was
present than when tau was either alone or bound to apoE2
or apoE3, whereas Thr231 was less phosphorylated when
apoE4 was present. It has been suggested that simultaneous
phosphorylation of multiple sites may be required for the
disruption of microtubule binding by tau and that double
phosphorylation at Thr212/Ser214 and Thr231/Ser235 may
be unique to PHF-tau [38]. Other results have indicated that
PHF-tau results from sequential phosphorylation that in-
cludes phosphorylation of Thr212 by GSK-3L followed by
Ser214 by PKA. If Ser214 is phosphorylated ¢rst, Thr212 is
thereby protected [39]. The modest, but consistent and statis-
tically signi¢cant isoform-speci¢c e¡ects shown here, in par-
ticular the increased phosphorylation of Thr212 in the pres-
ence of apoE4 and the failure to protect the Thr231/Ser235
peptide from phosphorylation may, therefore, have an e¡ect
by skewing the sequence of phosphorylation that leads to
PHF-tau. Similarly, the additional phosphopeptides seen
when apoE2 was present may represent sites which, readily
phosphorylated by GSK-3L, thereby prevent further phos-
phorylation by another kinase.
These results provide further evidence that GSK-3L is an
important, although not the only tau-kinase and provide fur-
ther experimental evidence to support the hypothesis that
apoE in£uences tau phosphorylation. Indeed in a recent study
in which human apoE4 was overexpressed in transgenic mice
[40], it was shown that apoE4 expression in neurones resulted
in an increase in phosphorylation of tau protein. Further
studies are planned to examine, using nano-ES MS, the phos-
phorylation of tau in neurones, to determine the signi¢cance
of any tau^apoE interaction in vivo.
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Fig. 3. Densitometric analysis of the phosphopeptide maps showing
the e¡ects of apoE isoform on tau phosphorylation by GSK-3L.
The relative intensity of each phosphopeptide spot (relative to the
summed intensity) averaged in each case from ¢ve experiments.
* indicates signi¢cant di¡erence 6 0.01 between apoE isoforms and
controls.
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